Cargando…

Predictors of Viral Non-Suppression among Patients Living with HIV under Dolutegravir in Bunia, Democratic Republic of Congo: A Prospective Cohort Study

The Democratic Republic of the Congo adopted the integrase inhibitor dolutegravir (DTG) as part of its preferred first-line HIV treatment regimen in 2019. This study aimed to identify predictors of viral non-suppression among HIV-infected patients under a DTG-based regimen in the context of ongoing...

Descripción completa

Detalles Bibliográficos
Autores principales: Buju, Roger T., Akilimali, Pierre Z., Kamangu, Erick N., Mesia, Gauthier K., Kayembe, Jean Marie N., Situakibanza, Hippolyte N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8834045/
https://www.ncbi.nlm.nih.gov/pubmed/35162109
http://dx.doi.org/10.3390/ijerph19031085
_version_ 1784649085204037632
author Buju, Roger T.
Akilimali, Pierre Z.
Kamangu, Erick N.
Mesia, Gauthier K.
Kayembe, Jean Marie N.
Situakibanza, Hippolyte N.
author_facet Buju, Roger T.
Akilimali, Pierre Z.
Kamangu, Erick N.
Mesia, Gauthier K.
Kayembe, Jean Marie N.
Situakibanza, Hippolyte N.
author_sort Buju, Roger T.
collection PubMed
description The Democratic Republic of the Congo adopted the integrase inhibitor dolutegravir (DTG) as part of its preferred first-line HIV treatment regimen in 2019. This study aimed to identify predictors of viral non-suppression among HIV-infected patients under a DTG-based regimen in the context of ongoing armed conflict since 2017 in the city of Bunia in the DRC. We conducted a cohort study of 468 patients living with HIV under DTG in all health facilities in Bunia. We calculated the proportion of participants with an HIV RNA of below 50 copies per milliliter. About three in four patients (72.8%) in this cohort had a viral load (VL) of <50 copies/mL after 6–12 months. After controlling for the effect of other covariates, the likelihood of having non-suppression remained significantly lower among the 25–34 age group and self-reported naïve patients with a baseline VL of ≥50 copies/mL. The likelihood of having non-suppression remained significantly higher among those who were at advanced stages of the disease, those with abnormal serum creatinine, those with high baseline HIV viremia over 1000 copies/mL, and the Sudanese ethnic group compared to the reference groups. This study suggests that we should better evaluate adherence, especially among adolescents and economically vulnerable populations, such as the Sudanese ethnic group in the city of Bunia. This suggests that an awareness of the potential effects of DTG and tenofovir is important for providers who take care of HIV-positive patients using antiretroviral therapy (ART), especially those with abnormal serum creatinine levels before starting treatment.
format Online
Article
Text
id pubmed-8834045
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88340452022-02-12 Predictors of Viral Non-Suppression among Patients Living with HIV under Dolutegravir in Bunia, Democratic Republic of Congo: A Prospective Cohort Study Buju, Roger T. Akilimali, Pierre Z. Kamangu, Erick N. Mesia, Gauthier K. Kayembe, Jean Marie N. Situakibanza, Hippolyte N. Int J Environ Res Public Health Article The Democratic Republic of the Congo adopted the integrase inhibitor dolutegravir (DTG) as part of its preferred first-line HIV treatment regimen in 2019. This study aimed to identify predictors of viral non-suppression among HIV-infected patients under a DTG-based regimen in the context of ongoing armed conflict since 2017 in the city of Bunia in the DRC. We conducted a cohort study of 468 patients living with HIV under DTG in all health facilities in Bunia. We calculated the proportion of participants with an HIV RNA of below 50 copies per milliliter. About three in four patients (72.8%) in this cohort had a viral load (VL) of <50 copies/mL after 6–12 months. After controlling for the effect of other covariates, the likelihood of having non-suppression remained significantly lower among the 25–34 age group and self-reported naïve patients with a baseline VL of ≥50 copies/mL. The likelihood of having non-suppression remained significantly higher among those who were at advanced stages of the disease, those with abnormal serum creatinine, those with high baseline HIV viremia over 1000 copies/mL, and the Sudanese ethnic group compared to the reference groups. This study suggests that we should better evaluate adherence, especially among adolescents and economically vulnerable populations, such as the Sudanese ethnic group in the city of Bunia. This suggests that an awareness of the potential effects of DTG and tenofovir is important for providers who take care of HIV-positive patients using antiretroviral therapy (ART), especially those with abnormal serum creatinine levels before starting treatment. MDPI 2022-01-19 /pmc/articles/PMC8834045/ /pubmed/35162109 http://dx.doi.org/10.3390/ijerph19031085 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Buju, Roger T.
Akilimali, Pierre Z.
Kamangu, Erick N.
Mesia, Gauthier K.
Kayembe, Jean Marie N.
Situakibanza, Hippolyte N.
Predictors of Viral Non-Suppression among Patients Living with HIV under Dolutegravir in Bunia, Democratic Republic of Congo: A Prospective Cohort Study
title Predictors of Viral Non-Suppression among Patients Living with HIV under Dolutegravir in Bunia, Democratic Republic of Congo: A Prospective Cohort Study
title_full Predictors of Viral Non-Suppression among Patients Living with HIV under Dolutegravir in Bunia, Democratic Republic of Congo: A Prospective Cohort Study
title_fullStr Predictors of Viral Non-Suppression among Patients Living with HIV under Dolutegravir in Bunia, Democratic Republic of Congo: A Prospective Cohort Study
title_full_unstemmed Predictors of Viral Non-Suppression among Patients Living with HIV under Dolutegravir in Bunia, Democratic Republic of Congo: A Prospective Cohort Study
title_short Predictors of Viral Non-Suppression among Patients Living with HIV under Dolutegravir in Bunia, Democratic Republic of Congo: A Prospective Cohort Study
title_sort predictors of viral non-suppression among patients living with hiv under dolutegravir in bunia, democratic republic of congo: a prospective cohort study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8834045/
https://www.ncbi.nlm.nih.gov/pubmed/35162109
http://dx.doi.org/10.3390/ijerph19031085
work_keys_str_mv AT bujurogert predictorsofviralnonsuppressionamongpatientslivingwithhivunderdolutegravirinbuniademocraticrepublicofcongoaprospectivecohortstudy
AT akilimalipierrez predictorsofviralnonsuppressionamongpatientslivingwithhivunderdolutegravirinbuniademocraticrepublicofcongoaprospectivecohortstudy
AT kamanguerickn predictorsofviralnonsuppressionamongpatientslivingwithhivunderdolutegravirinbuniademocraticrepublicofcongoaprospectivecohortstudy
AT mesiagauthierk predictorsofviralnonsuppressionamongpatientslivingwithhivunderdolutegravirinbuniademocraticrepublicofcongoaprospectivecohortstudy
AT kayembejeanmarien predictorsofviralnonsuppressionamongpatientslivingwithhivunderdolutegravirinbuniademocraticrepublicofcongoaprospectivecohortstudy
AT situakibanzahippolyten predictorsofviralnonsuppressionamongpatientslivingwithhivunderdolutegravirinbuniademocraticrepublicofcongoaprospectivecohortstudy